GlassScriptPhysician profile
Crystal L Snider
NPI 1700098845
$1,811.90
in general payments reported to CMS, 2019-2025
29 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $432 · 2020: $160 · 2021: $386 · 2022: $374 · 2023: $380 · 2024: $80.31.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $460.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $460.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $325.54 | 2021-2024 | Qulipta, Vraylar |
| Pfizer INC. | $221.51 | 2019-2023 | |
| Astrazeneca Pharmaceuticals LP | $204.33 | 2019-2023 | Farxiga, Breztri |
| Novartis Pharmaceuticals Corporation | $151.53 | 2019-2023 | |
| Amgen INC. | $145.70 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $64.54 | 2020-2023 | Eliquis |
| Supernus Pharmaceuticals, INC. | $64.15 | 2021-2023 | Qelbree |
| Takeda Pharmaceuticals U.S.A., INC. | $59.86 | 2019-2021 | |
| Genentech USA, INC. | $53.02 | 2019-2020 | |
| Novo Nordisk INC | $49.55 | 2022-2023 | Rybelsus, Ozempic |
| Bayer Healthcare Pharmaceuticals INC. | $44.00 | 2022-2023 | |
| Exact Sciences Corporation | $42.40 | 2023 | Cologuard Collection Kit |
| Abbott Laboratories | $35.95 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $34.59 | 2022-2023 | |
| Ceribell, INC. | $34.02 | 2024 | Pocket Eeg Device |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $33.85 | 2022 | |
| Lilly USA, LLC | $29.99 | 2020-2023 | Mounjaro |
| Dexcom, INC. | $28.05 | 2021 | |
| Corium, LLC | $27.14 | 2023 | Azstarys |
| Almatica Pharma LLC | $20.51 | 2022 | |
| Aimmune Therapeutics, INC. | $19.62 | 2024 | |
| Sanofi Pasteur INC. | $19.22 | 2019 | |
| Janssen Pharmaceuticals, INC | $18.20 | 2019 | |
| Amarin Pharma, INC. | $17.36 | 2022 | |
| Sanofi-Aventis U.S. LLC | $16.79 | 2022 | |
| Idorsia Pharmaceuticals US INC | $14.25 | 2023 | Quviviq |
| Exeltis, USA INC. | $13.58 | 2022 | |
| Inogen, INC. | $11.67 | 2022 | |
| Ironshore Pharmaceuticals INC. | $10.98 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Crystal Snider listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.